Detalles de la búsqueda
1.
A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland.
Scand J Gastroenterol
; 56(6): 661-670, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33820465
2.
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Scand J Gastroenterol
; 54(6): 718-725, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31184512
3.
Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Scand J Gastroenterol
; 52(12): 1348-1353, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28838273
4.
Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
Eur J Gastroenterol Hepatol
; 34(11): 1125-1131, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36170681
5.
Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease.
J Crohns Colitis
; 15(6): 1019-1031, 2021 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33300552
6.
Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
Medicine (Baltimore)
; 99(2): e18723, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31914087
7.
Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort.
Eur J Gastroenterol Hepatol
; 32(12): 1507-1513, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32868649
Resultados
1 -
7
de 7
1
Próxima >
>>